■评估和评估血清中骨代谢标志物骨钙蛋白和β-Cross-Laps的指标,作为监测下颌骨切除术和重建术后患者骨再生和确定植入时间的工具。游离腓骨瓣随后进行骨膜植入。
■为期6年的48名患者参加了这项研究,由于肿瘤切除。所有患者在肿瘤切除后行腓骨游离皮瓣重建,骨切除术后4-6个月,牙科植入物安装与进一步的矫形康复。为了评估移植后的骨重建率,用酶免疫法测定骨重塑中骨钙素和β-Cross-Laps血清生化指标的含量。
■所有46例腓骨游离皮瓣均愈合,无并发症,均存活。总共安装了326个植入物,8个植入物骨整合失败,和6个植入物失败后5年的负荷(种植体周围炎)。5年后植入成功率为95,7%。在手术前的患者中,平均骨钙蛋白水平为8.5ng/ml,两个月后,骨钙蛋白含量急剧增加15.4ng/ml,四个月后达到24.7ng/ml,在28.6ng/ml的六个月后,然后指标开始下降,12个月后接近14.7ng/ml的标准。在手术前的患者中,β-Cross-Laps的平均水平为0.76ng/ml,骨移植两个月后,β-Cross-Laps的平均水平降至-0.65ng/ml,四个月后,指标增加,达到0.98ng/ml,六个月后,指标为-1.56ng/ml,然后这些指标开始下降,12个月后,接近正常值-0.87ng/ml。不同浓度的骨钙蛋白或β-交叉圈与植入物的成功率之间存在相关性。植入物显示血清中低浓度的骨钙蛋白和高浓度的β-Cross-Laps不成功。
■研究表明,放置在重建区域的植入物的长期生存率和成功率可以保证植入物支持的假体的良好预后。血清骨钙蛋白和β-Cross-Laps中的骨标志物可用于评估骨重建率,这可以让你确定植入的时间。
UNASSIGNED: To evaluate and assess the indicators of bone metabolism markers osteocalcin and β-Cross-Laps in blood serum as a tool for monitoring bone regeneration and determining the time of implantation in patients after mandibulectomy and reconstruction of a free fibular flap with subsequent endosteal implants.
UNASSIGNED: Forty-eight patients in a 6-year period participated in this study, due to resection for tumors. All patients underwent reconstruction with fibula free flap after tumor resection, 4-6 months after osteoectomy, dental implants were installed with further orthopedic rehabilitation. To assess the rate of bone remodeling after transplantation, the content biochemical markers of bone remodeling osteocalcin and β-Cross-Laps serum were determined by enzyme immunoassay.
UNASSIGNED: All 46 fibular free flaps were healed without complications and were survived. A total 326 implants installed, 8 implants failed to osseointegrate, and 6 implants failed after 5 years of loading (peri-implantitis). Success rate of implants after 5 years was 95,7%. In patients before surgery, the mean of osteocalcin levels was 8.5 ng/ml, two months later, there was a sharp increase in the content of osteocalcin by 15.4 ng/ml, after four months reached 24.7 ng/ml, after six months of 28.6 ng/ml, then the indicator began to decrease and after 12 months it was approaching the norm of 14.7 ng/ml. In patients before surgery, the mean level of β-Cross-Laps was 0.76 ng/ml, after two months bone transplantation the mean level of β-Cross-Laps decreased to - 0.65 ng/ml, after four months the indicator increased and reached of 0.98 ng/ml, after six months the indicator was - 1.56 ng/ml, then these indicators began to decrease and after 12 months, approaching normal values of - 0.87 ng/ml. There is a correlation between different concentrations of osteocalcin or β-Cross- Laps and the success rate of implants. Implants were shown to be unsuccessful low concentrations of osteocalcin and high concentrations of β-Cross-Laps in serum.
UNASSIGNED: Studies have shown that the long-term survival and success rates of implants placed in the reconstructed areas may guarantee an excellent prognosis of implant-supported prostheses. Bone markers in blood serum osteocalcin and β-Cross-Laps can be used to evaluate the rate of bone remodeling, which allows you to determine the time of implantation.